Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
Gilead’s Phase 3 ARTISTRY-2 trial demonstrated its investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was non-inferior to BIKTARVY in virologically suppressed HIV patients.
TuHURA Biosciences released 1,539,958 shares of common stock to legacy Kintara Therapeutics stockholders as a result of meeting a contractual safety milestone for REM-001.
